CN105348318A - 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications - Google Patents

2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications Download PDF

Info

Publication number
CN105348318A
CN105348318A CN201510764230.XA CN201510764230A CN105348318A CN 105348318 A CN105348318 A CN 105348318A CN 201510764230 A CN201510764230 A CN 201510764230A CN 105348318 A CN105348318 A CN 105348318A
Authority
CN
China
Prior art keywords
title complex
alpha
benzoyl hydrazone
ketobutyric acid
acid benzoyl
Prior art date
Application number
CN201510764230.XA
Other languages
Chinese (zh)
Inventor
谭宇星
蒋伍玖
邝代治
庾江喜
朱小明
张复兴
冯泳兰
Original Assignee
衡阳师范学院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 衡阳师范学院 filed Critical 衡阳师范学院
Priority to CN201510764230.XA priority Critical patent/CN105348318A/en
Publication of CN105348318A publication Critical patent/CN105348318A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/22Tin compounds
    • C07F7/2284Compounds with one or more Sn-N linkages

Abstract

The invention discloses a 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex. The complex is a complex with a structural formula (I) shown in the specification, and Ph is phenyl. The invention also discloses a preparation method for a 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex and applications in preparation of anticancer medicines.

Description

A kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex and its preparation method and application

Technical field

The present invention relates to a kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex and preparation method thereof, and this ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex is preparing the application in cancer therapy drug.

Background technology

Organotin is the organometallics that a class contains Sn-C key.Researcher just noticed the Anticancer Activity in vitro of organo-tin compound before very early.1972, Brown Late Cambrian Ph 3snOOCCH 3inhibited to the growth of mouse cancer cells.1980, the research of the chemists such as Crowe showed, many organo-tin compounds have anti tumor activity in vitro.1989, American National anticancer research institute (NationalCancerInstitute) has carried out antitumor activity screening to more than 2,000 kinds of organo-tin compounds, and result shows that some organo-tin compounds have restraining effect to P388 Lymphocytic leukemia.2002, the people such as Gielen were doing comprehensive summing up to the activity of organotin carboxylate's ester cpds, thought that many organo-tin compounds have good Anticancer Activity in vitro really after research.

Research shows, the part of the organic group that organotin atom connects and participation coordination decides the biological activity of organo-tin compound, selects the tin atom coordination in some organic ligands with good biological activity itself and organotin to cause the great interest of people.Acylhydrazone is by a class Schiff compound of hydrazide kind compound modification, they are formed by aldehydes or ketones and hydrazides condensation, there is good biological activity, stronger coordination ability and various coordination mode, and have a wide range of applications in medicine, agricultural chemicals, material and analytical reagent etc.In recent years, domestic and international many researchists compare it and in depth study in biological activity, and research finds that acylhydrazone has the various active such as anticancer, sterilization, anti-inflammatory.Therefore, acylhydrazone class Schiff part is combined with organotin, attempts to obtain the stronger new compound of biological activity, become the interested research direction of people.

Chinese patent CN102718794A discloses a kind of pair of acylhydrazone class Schiff tin diphenyl title complex and the application in the medicine preparing anti-lung gland cancer, colorectal carcinoma, leukemia cell thereof.

Chinese patent CN101851251A discloses a kind of dibutyl tin title complex of acylhydrazone class Schiff part and is preparing the application in Hepatoma therapy, adenocarcinoma of lung, mammary cancer, prostate cancer, colorectal carcinoma or the leukemic medicine of young grain morning.

Document (JournalofOrganometallicChemistry, 2014,75:83-91) report, organotin acylhydrazone class Schiff base complex has comparatively strong biological activity to human colon cancer cell (HCT-116), human lung adenocarcinoma cell (A549), Human umbilical vein endothelial cells (HUVEC), and is better than carboplatin.

Document (JournalofOrganometallicChemistry, 2013,724:23-31) report, serial organotin acylhydrazone class Schiff base complex, organo-tin compound and acylhydrazone class Schiff part are respectively to the restraining effect of the cancer cells such as human lung adenocarcinoma cell (A549), human colon cancer cell (HCT-8), people in loop (hl-60).

Document (Bioorganic & MedicinalChemistryLetters, 2015,25:4461-4463) is reported, multiple acylhydrazone class Schiff part is to the antitumour activity of human liver cancer cell (HuH-7) and human lung adenocarcinoma cell (A549).

The experiment proved that the material with antitumour activity based on acylhydrazone class Schiff organotin complex, the present invention selects the acid of benzoyl hydrazine, 2-butanone to react with phenylbenzene tindichloride under certain condition, synthesis obtains title complex human colon cancer cell (Colo205), human liver cancer cell (HepG2), breast cancer cell (MCF7), cervical cancer cell (Hela) and human lung carcinoma cell (NCI-H460) to certain inhibit activities, for exploitation cancer therapy drug provides new approach.

Summary of the invention

The first object of the present invention there is provided a kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.

The second object of the present invention is to provide above-mentioned ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl complex preparation method.

The third object of the present invention is to provide above-mentioned ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex and is preparing the application in cancer therapy drug.

As a kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of a first aspect of the present invention, it is the title complex of structural formula (I)

(I)

Wherein Ph is phenyl.

ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of the present invention is through ultimate analysis, infrared spectra, nuclear magnetic resonance spectrum and the structural analysis of X-ray single crystal diffraction, and result is as follows:

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of the present invention is crystalline structure, its crystal is oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

The constructional feature of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of the present invention is: in molecule, tin atom is hexa-coordinate distorted octahedron configuration.

As the preparation method of a kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of a second aspect of the present invention; phenylbenzene tindichloride, benzoyl hydrazine, 2-butanone acid and solvent anhydrous methanol is added in the reaction vessel having nitrogen protection; be react 5 ~ 24h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; under the condition of 20 ~ 35 DEG C, control solvent evaporates crystallization, obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.

In a preferred embodiment of the invention, the amount of substance of described phenylbenzene tindichloride, benzoyl hydrazine, 2-butanone acid three is than being 1:(1 ~ 1.05): (1.05 ~ 1.15).

In a preferred embodiment of the invention, described solvent anhydrous methanol consumption is that every mmole phenylbenzene tindichloride adds 15 ~ 35 milliliters.

ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl complex preparation method of the present invention is one kettle way, adds direct reaction in reactor together by whole raw material, without the separation of intermediate, directly prepares ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.And the customary preparation methods of this area is for first to prepare part, again part and metallic starting compound are reacted and prepare title complex, ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl complex preparation method of the present invention compares this area customary preparation methods, there is the last handling process saving intermediate steps, save the advantages such as a large amount of human and material resources, financial resources.

A kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex as a third aspect of the present invention is preparing the application in cancer therapy drug.

Applicant has carried out anti tumor activity in vitro to above-mentioned ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex and has determined research, confirm ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex and there is certain anticancer bioactive, that is the purposes of above-mentioned title complex is preparing the application in cancer therapy drug, is exactly the application in the anti-human colorectal carcinoma of preparation, people's liver cancer, human breast carcinoma, human cervical carcinoma, people's lung-cancer medicament specifically.

ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of the present invention demonstrates good antitumour activity to human colon cancer cell, human liver cancer cell, human breast cancer cell, human cervical carcinoma cell, human lung carcinoma cell etc., the features such as ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex antitumour activity of the present invention is high, cost is low, preparation method is simple, provide new way for developing new cancer therapy drug.

Accompanying drawing explanation

Fig. 1 is the IR spectrogram of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.

Fig. 2 is ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex 1hNMR spectrogram.

Fig. 3 is ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex 13cNMR spectrogram.

Fig. 4 is ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex 119snNMR spectrogram.

Fig. 5 is the crystalline structure figure of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.

Fig. 6 is the TG-DTG curve of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.

Embodiment

Further describe the present invention by following examples, but scope of the present invention should be noted not by any restriction of these embodiments.

Embodiment 1:

The preparation of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex:

0.344g (1.0mmol) phenylbenzene tindichloride, 0.136g (1.0mmol) benzoyl hydrazine, the acid of 0.112g (1.1mmol) 2-butanone and 25mL solvent anhydrous methanol is added in the 100mL there-necked flask having nitrogen protection; be react 8h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; solvent evaporates crystallization is controlled under the condition of 20 ~ 35 DEG C; obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.Productive rate: 88.5%.Fusing point: 260 ~ 262 DEG C (dec).

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

Crystallographic data: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

Embodiment 2:

The preparation of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex:

0.344g (1.0mmol) phenylbenzene tindichloride, 0.136g (1.0mmol) benzoyl hydrazine, the acid of 0.107g (1.05mmol) 2-butanone and 35mL solvent anhydrous methanol is added in the 100mL there-necked flask having nitrogen protection; be react 5h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; solvent evaporates crystallization is controlled under the condition of 20 ~ 35 DEG C; obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.Productive rate: 87.4%.Fusing point: 260 ~ 262 DEG C (dec).

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

Crystallographic data: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

Embodiment 3:

The preparation of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex:

0.344g (1.0mmol) phenylbenzene tindichloride, 0.142g (1.05mmol) benzoyl hydrazine, the acid of 0.117g (1.15mmol) 2-butanone and 30mL solvent anhydrous methanol is added in the 100mL there-necked flask having nitrogen protection; be react 15h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; solvent evaporates crystallization is controlled under the condition of 20 ~ 35 DEG C; obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.Productive rate: 87.7%.Fusing point: 260 ~ 262 DEG C (dec).

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

Crystallographic data: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

Embodiment 4:

The preparation of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex:

1.720g (5.0mmol) phenylbenzene tindichloride, 0.694g (5.1mmol) benzoyl hydrazine, the acid of 0.551g (5.4mmol) 2-butanone and 100mL solvent anhydrous methanol is added in the 250mL there-necked flask having nitrogen protection; be react 20h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; solvent evaporates crystallization is controlled under the condition of 20 ~ 35 DEG C; obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.Productive rate: 83.0%.Fusing point: 260 ~ 262 DEG C (dec).

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

Crystallographic data: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

Embodiment 5:

The preparation of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex:

1.720g (5.0mmol) phenylbenzene tindichloride, 0.707g (5.2mmol) benzoyl hydrazine, the acid of 0.571g (5.6mmol) 2-butanone and 150mL solvent anhydrous methanol is added in the 250mL there-necked flask having nitrogen protection; be react 22h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; solvent evaporates crystallization is controlled under the condition of 20 ~ 35 DEG C; obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.Productive rate: 83.2%.Fusing point: 260 ~ 262 DEG C (dec).

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

Crystallographic data: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

Embodiment 6:

The preparation of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex:

3.440g (10.0mmol) phenylbenzene tindichloride, 1.387g (10.2mmol) benzoyl hydrazine, the acid of 1.081g (10.6mmol) 2-butanone and 150mL solvent anhydrous methanol is added in the 250mL there-necked flask having nitrogen protection; be react 24h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; solvent evaporates crystallization is controlled under the condition of 20 ~ 35 DEG C; obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.Productive rate: 83.7%.Fusing point: 260 ~ 262 DEG C (dec).

Ultimate analysis (C 23h 20n 2o 3sn): calculated value: C56.25, H4.10, N5.70; Measured value: C56.24, H4.09, N5.75.

FT-IR(KBr,ν/cm -1):3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453。

1HNMR(500MHz,CDCl 3)δ(ppm):8.33-8.35(m,2H),7.81-7.83(m,4H),7.60(t, J=7.4Hz,1H),7.45-7.53(m,8H,Ph-H),3.11(q, J=7.6Hz,2H),1.31(t, J=7.5Hz,3H)。

13CNMR(125MHz,CDCl 3)δ(ppm):174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70。

119SnNMR(187MHz,CDCl 3)δ(ppm):-284.66。

Crystallographic data: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984.

Test example:

ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of the present invention, its Anticancer Activity in vitro is measured and is realized by MTT experiment method.

MTT analytical method:

Based on metabolism reduction 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide.Succinodehydrogenase in viable cell plastosome can make exogenous MTT be reduced to water-insoluble bluish voilet crystallization first a ceremonial jade-ladle, used in libation (Formazan) and be deposited in cell, and dead cell is without this function.First a ceremonial jade-ladle, used in libation in dimethyl sulfoxide (DMSO) (DMSO) energy dissolved cell, measures the optical density(OD) of characteristic wavelength, can indirectly reflect viable cell quantity by microplate reader.

Mtt assay is adopted to measure the ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of embodiment 1 preparation to the inhibit activities of human colon cancer cell (Colo205), human liver cancer cell (HepG2), human breast cancer cell (MCF7), human cervical carcinoma cell (Hela) and human lung carcinoma cell (NCI-H460).

Cell strain and culture system: Colo205, HepG2, MCF7, Hela and NCI-H460 cell strain takes from American. tissue incubator (ATCC).RPMI1640(GIBICO company with containing 10% foetal calf serum) substratum, in 5%(volume fraction) CO 2, carry out vitro culture in 37 DEG C of saturated humidity incubators.

Test process: join in each hole respectively by testing the concentration gradient of liquid (0.1ng/mL ~ 10ug/mL) according to concentration, each concentration establishes 6 parallel holes.Experiment is divided into drug study group (adding the test medicine of different concns respectively), control group (only add nutrient solution and cell, do not add test medicine) and blank group (only add cultivation medicine, do not add cell and test medicine).Orifice plate after dosing is placed in 37 DEG C, 5%CO 272h is cultivated in incubator.The activity of control drug measures according to the method for test sample.In orifice plate after having cultivated 72h, every hole adds MTT40uL(D-Hanks damping fluid and is made into 4mg/mL).After placing 4h at 37 DEG C, remove supernatant liquid.Every hole adds 150uLDMSO, and vibration 5min, makes Formazan dissolving crystallized.Finally, automatic microplate reader is utilized to detect the optical density(OD) in each hole at 570nm wavelength place.

Data processing: data processing uses GraphPadPrismversion5.0 program, title complex IC 50carry out matching by the nonlinear regression model (NLRM) in program with S shape dose response to obtain.

With MTT analytical method, human colon cancer cell (Colo205), human liver cancer cell (HepG2), human breast cancer cell (MCF7), human cervical carcinoma cell (Hela) and human lung carcinoma cell (NCI-H460) cell strain are analyzed, measure its IC 50value, result is as shown in table 1, conclusion is: from data in table, cancer therapy drug is used as with ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex of the present invention, to human colon cancer cell (Colo205), human liver cancer cell (HepG2), human breast cancer cell (MCF7), human cervical carcinoma cell (Hela) and human lung carcinoma cell (NCI-H460), there is certain drug effect, can be used as the candidate compound of cancer therapy drug.

Table 12-carbonyl butyric acid benzoyl hydrazone tin diphenyl title complex cancer therapy drug external activity test data.

ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex prepared by all the other embodiments is with the same test example of antitumour activity testing method of mtt assay to human colon cancer cell (Colo205), human liver cancer cell (HepG2), human breast cancer cell (MCF7), human cervical carcinoma cell (Hela) and human lung carcinoma cell (NCI-H460), and test result and table 1 are substantially identical.

Claims (10)

1. an ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex, the title complex for following structural formula (I):
(I)
Wherein Ph is phenyl.
2. as claimed in claim 1 containing a kind of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex, its ir data: FT-IR (KBr, ν/cm -1): 3047,2978,2935,1635,1598,1502,1342,1298,1201,1174,1064,972,732,715,694,588,453; Its nuclear-magnetism modal data: 1hNMR (500MHz, CDCl 3) δ (ppm): 8.33-8.35 (m, 2H), 7.81-7.83 (m, 4H), 7.60 (t, j=7.4Hz, 1H), 7.45-7.53 (m, 8H, Ph-H), 3.11 (q, j=7.6Hz, 2H), 1.31 (t, j=7.5Hz, 3H); 13cNMR (125MHz, CDCl 3) δ (ppm): 174.79,163.26,160.26,136.14,135.68,132.83,132.26,131.42,129.40,126.75,128.49,21.21,10.70; 119snNMR (187MHz, CDCl 3) δ (ppm) :-284.66.
3. ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex as claimed in claim 1, wherein, described ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex is crystalline structure, and its crystallographic data is as follows: oblique system, spacer P2 (1)/n, a=1.18100 (7) nm, b=0.89659 (5) nm, c=2.02830 (11) nm, α=γ=90 °, β=99.8920 (10) °, Z=4, V=2.1158 (2) nm 3, Dc=1.542Mgm -3, m (MoK α)=1.233mm -1, F (000)=984; In molecule, tin atom is hexa-coordinate distorted octahedron configuration.
4. described in claim 1, ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex has certain thermally-stabilised scope, can stable existence below 260 DEG C.
5. the preparation method of ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex according to claim 1; it is characterized in that in the reaction vessel having nitrogen protection, add phenylbenzene tindichloride, benzoyl hydrazine, 2-butanone acid and solvent anhydrous methanol; be react 5 ~ 24h under the condition of 45 ~ 65 DEG C in temperature; cooling; filter; under the condition of 20 ~ 35 DEG C, control solvent evaporates crystallization, obtain colourless transparent crystal, be ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex.
6. the method for preparation as claimed in claim 5, is characterized in that, the amount of substance of described phenylbenzene tindichloride, benzoyl hydrazine, 2-butanone acid three is than being 1:(1 ~ 1.05): (1.05 ~ 1.15).
7. the method for preparation as claimed in claim 5, it is characterized in that, described solvent anhydrous methanol consumption is that every mmole phenylbenzene tindichloride adds 15 ~ 35 milliliters.
8. the method for preparation as claimed in claim 5, is characterized in that, adopts one kettle way preparation.
9. described in claim 1, ALPHA-ketobutyric acid benzoyl hydrazone tin diphenyl title complex is preparing the application in cancer therapy drug.
10. application according to claim 9, wherein said cancer cells is human colon cancer cell, human liver cancer cell, human breast cancer cell, human cervical carcinoma cell, human lung carcinoma cell.
CN201510764230.XA 2015-11-11 2015-11-11 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications CN105348318A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510764230.XA CN105348318A (en) 2015-11-11 2015-11-11 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510764230.XA CN105348318A (en) 2015-11-11 2015-11-11 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications

Publications (1)

Publication Number Publication Date
CN105348318A true CN105348318A (en) 2016-02-24

Family

ID=55324399

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510764230.XA CN105348318A (en) 2015-11-11 2015-11-11 2-carbonyl butyric acid benzoyl hydrazone dibenzyl tin complex, preparation method therefor and applications

Country Status (1)

Country Link
CN (1) CN105348318A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646568A (en) * 2016-04-11 2016-06-08 衡阳师范学院 2-oxo-propionic acid salicyloyl hydrazone diphenyltin complex as well as preparation method and application thereof
CN106220675A (en) * 2016-08-28 2016-12-14 衡阳师范学院 A kind of 2 carbonyl butanoic acid are to tert-butyl benzoyl hydrazone stannous phenide coordination compound and its preparation method and application
CN106220677A (en) * 2016-08-28 2016-12-14 衡阳师范学院 A kind of 2 carbonyl butanoic acid are to toluyl hydrazone di-n-butyl tin coordination compound and its preparation method and application
CN106279260A (en) * 2016-08-20 2017-01-04 衡阳师范学院 A kind of 2 carbonyl butanoic acid salicyloyl hydrazone di-n-butyl tin coordination compounds and its preparation method and application
CN106317103A (en) * 2016-08-13 2017-01-11 衡阳师范学院 2-carbonyl butyrate p-hydroxy benzoyl hydrazone di-n-butyltin complex and preparation method and application thereof
CN106336429A (en) * 2016-08-28 2017-01-18 衡阳师范学院 2-oxo-butyric acid p-methyl benzoyl hydrazone diphenyl tin complex and preparation method and application thereof
CN106366120A (en) * 2016-08-30 2017-02-01 衡阳师范学院 2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex and preparation method and application thereof
CN106380480A (en) * 2016-08-30 2017-02-08 衡阳师范学院 2-oxobutyric acid p-nitrobenzoyl hydrazone dibenzyl tin complex and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060869A (en) * 2010-12-14 2011-05-18 聊城大学 Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060869A (en) * 2010-12-14 2011-05-18 聊城大学 Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S. W. FOO等,: "Synthesis and characterization of novel diorganotin(IV) complexes derived from N-benzoylhydrazinoacetic acid methyl ester: X-ray crystal structure of [Ph2Sn(MPB)]", 《ACGC CHEMICAL RESEARCH COMMUNICATIONS》 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105646568A (en) * 2016-04-11 2016-06-08 衡阳师范学院 2-oxo-propionic acid salicyloyl hydrazone diphenyltin complex as well as preparation method and application thereof
CN106317103A (en) * 2016-08-13 2017-01-11 衡阳师范学院 2-carbonyl butyrate p-hydroxy benzoyl hydrazone di-n-butyltin complex and preparation method and application thereof
CN106279260A (en) * 2016-08-20 2017-01-04 衡阳师范学院 A kind of 2 carbonyl butanoic acid salicyloyl hydrazone di-n-butyl tin coordination compounds and its preparation method and application
CN106279260B (en) * 2016-08-20 2018-11-27 衡阳师范学院 A kind of ALPHA-ketobutyric acid salicyloyl hydrazone di-n-butyl tin complex and its preparation method and application
CN106220675A (en) * 2016-08-28 2016-12-14 衡阳师范学院 A kind of 2 carbonyl butanoic acid are to tert-butyl benzoyl hydrazone stannous phenide coordination compound and its preparation method and application
CN106220677A (en) * 2016-08-28 2016-12-14 衡阳师范学院 A kind of 2 carbonyl butanoic acid are to toluyl hydrazone di-n-butyl tin coordination compound and its preparation method and application
CN106336429A (en) * 2016-08-28 2017-01-18 衡阳师范学院 2-oxo-butyric acid p-methyl benzoyl hydrazone diphenyl tin complex and preparation method and application thereof
CN106366120A (en) * 2016-08-30 2017-02-01 衡阳师范学院 2-carbonyl butyric acid p-metoxybenzene formyl hydrazone diphenyl tin complex and preparation method and application thereof
CN106380480A (en) * 2016-08-30 2017-02-08 衡阳师范学院 2-oxobutyric acid p-nitrobenzoyl hydrazone dibenzyl tin complex and preparation method and application thereof
CN106380480B (en) * 2016-08-30 2018-11-27 衡阳师范学院 A kind of ALPHA-ketobutyric acid p-nitrophenyl formyl hydrazone stannous phenide complex and its preparation method and application
CN106366120B (en) * 2016-08-30 2019-02-19 衡阳师范学院 A kind of ALPHA-ketobutyric acid is to methoxybenzoyl hydrazone stannous phenide complex and its preparation method and application

Similar Documents

Publication Publication Date Title
Wu et al. Stabilization of G‐Quadruplex DNA with Platinum (II) Schiff Base Complexes: Luminescent Probe and Down‐Regulation of c‐myc Oncogene Expression
Meyer et al. Gold (I) N‐heterocyclic carbene complexes with naphthalimide ligands as combined thioredoxin reductase inhibitors and DNA intercalators
Roth et al. Trinuclear copper (II) complexes derived from Schiff-base ligands based on a 6-amino-6-deoxyglucopyranoside: structural and magnetic characterization
CN101503423B (en) Parachlorobenzoyl hydrazone organotin complex, preparation and use
Catalan et al. Reactions of DNA purines with dirhodium formamidinate compounds that display antitumor behavior
CN102408452B (en) Tetrapyridylporphine bridged crossed tetra-palladium complexes, and preparation method and antitumor activity thereof
Annaraj et al. Synthesis, structure information, DNA/BSA binding affinity and in vitro cytotoxic studies of mixed ligand copper (II) complexes containing a phenylalanine derivative and diimine co-ligands
Gondolova et al. Synthesis, crystal structure and biological evaluation of spectroscopic characterization of Ni (II) and Co (II) complexes with N‐salicyloil‐N′‐maleoil‐hydrazine as anticholinergic and antidiabetic agents
CN103396436B (en) Monobutyltin substituted salicylic aldehydes contracting arylamine Schiff base complex and preparation method and application
CN105384702B (en) Three substitution s-triazine compounds and preparation method thereof
CN105198921B (en) A kind of 2- carbonyl -2- phenylacetic acid salicyloyl hydrazone dibutyl tin complex and its preparation method and application
CN102060869A (en) Tindiphenyl (IV) coordination compound of benzoylformic acid-3-hydroxyl-2-naphthyl formyl hydrazone as well as preparation method and application thereof
CN105237564B (en) A kind of phenylpropionic acid salicyloyl hydrazone two of 2 carbonyl 3 is to methyl-benzyl tin complex and its preparation method and application
CN103288684B (en) Biphenyl carbamide compound with antineoplastic activity and preparation method thereof
Dawn et al. Supramolecular gel control of cisplatin crystallization: Identification of a new solvate form using a cisplatin-mimetic gelator
CN106632424B (en) Using 1- (2- pyridines) -9- benzyls-B-carboline as the chlorination copper complex and its synthetic method of ligand and application
CN104817493A (en) Aromatic heterocyclic amide substituted diarylurea compound, preparation method and application thereof
CN103509046B (en) Two [three (2-methyl-2-phenyl propyl) tin] dicarboxylic esters and preparation method and application
Martins et al. Conformational polymorphism in racemic crystals of the diuretic drug chlortalidone
Tirkey et al. Synthesis, characterization and antibacterial studies of ferrocenyl and cymantrenyl hydrazone compounds
Chattopadhyay et al. A novel copper (II) complex with a pendant Schiff base: An unprecedented monodentate bonding mode of the potentially tridentate ligand
CN103058960A (en) Cabazitaxel polymorphic form and preparation method thereof
CN103113420B (en) A kind of dibutyl tin oxygen duster compound containing ferrocenyl and preparation method and application
CN105237563B (en) A kind of 2 carbonyl propionic acid para hydroxybenzene formyl hydrazone two (2,4 dichloro benzyl) tin complexs and its preparation method and application
CN105384770B (en) A kind of 2 carbonyl propionic acid salicyloyl hydrazones two are to methyl-benzyl tin complex and its preparation method and application

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160224

RJ01 Rejection of invention patent application after publication